Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity
Open Access
- 5 January 2010
- journal article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 102 (3), 495-499
- https://doi.org/10.1038/sj.bjc.6605514
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Combination targeted therapy in advanced renal cell carcinomaCancer, 2009
- Combination Targeted Therapy With Sorafenib and Bevacizumab Results in Enhanced Toxicity and Antitumor ActivityJournal of Clinical Oncology, 2008
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapyCancer, 2008
- Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast CancerNew England Journal of Medicine, 2007
- Phase II Study of Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer or Peritoneal Serous CancerJournal of Clinical Oncology, 2007
- Phase II Trial of Bevacizumab in Persistent or Recurrent Epithelial Ovarian Cancer or Primary Peritoneal Cancer: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2007
- Proteins, drug targets and the mechanisms they control: the simple truth about complex networksNature Reviews Drug Discovery, 2007
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Treatment of Metastatic Renal Cell Carcinoma With a Combination of Bevacizumab and ErlotinibJournal of Clinical Oncology, 2005